Cite
[Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)].
MLA
Thanh, T.Nguyen, et al. “[Long-Term Efficacy and Tolerance of Stiripentaol in Severe Myoclonic Epilepsy of Infancy (Dravet’s Syndrome)].” Archives de Pediatrie : Organe Officiel de La Societe Francaise de Pediatrie, vol. 9, no. 11, Nov. 2002, pp. 1120–27. EBSCOhost, https://doi.org/10.1016/s0929-693x(02)00090-8.
APA
Thanh, T. N., Chiron, C., Dellatolas, G., Rey, E., Pons, G., Vincent, J., & Dulac, O. (2002). [Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome)]. Archives de Pediatrie : Organe Officiel de La Societe Francaise de Pediatrie, 9(11), 1120–1127. https://doi.org/10.1016/s0929-693x(02)00090-8
Chicago
Thanh, T Nguyen, C Chiron, G Dellatolas, E Rey, G Pons, J Vincent, and O Dulac. 2002. “[Long-Term Efficacy and Tolerance of Stiripentaol in Severe Myoclonic Epilepsy of Infancy (Dravet’s Syndrome)].” Archives de Pediatrie : Organe Officiel de La Societe Francaise de Pediatrie 9 (11): 1120–27. doi:10.1016/s0929-693x(02)00090-8.